The 2026 Nobel Prize in Medicine Awarded to Optogenetics: The Discovery That Switches the Brain On and Off with Light
In this article
Medical content reviewed by Prof. Dr. Mustafa Özdoğan · Last updated: October 2026
The 2026 Nobel Prize in Physiology or Medicine, for "discoveries concerning light-gated ion channels and optogenetics," was awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel as the recipients. A protein that enables a green alga to swim toward light has become a tool that switches selected cells in the brain on and off with light within milliseconds. This tool changed the way we understand the brain and reached the first treatments for blindness.
- Prize: Announced by the Nobel Assembly at Karolinska Institutet on 5 October 2026; the prize of 12 million Swedish kronor was divided equally among the three scientists.
- Discovery: Nagel and Hegemann showed in 2002-2003 that channelrhodopsins in green algae are light-gated ion channels. Deisseroth and his team stimulated mammalian nerve cells with light using this channel in 2005 and named the method "optogenetics" in 2006.
- Importance: By switching a specific cell type on and off at a specific moment, it became possible to directly test which cell is responsible for which behavior; brain research moved from observation to cause-and-effect experiments.
- Clinical status: There is no approved optogenetic treatment yet. In the USA, the authorization application for the first gene therapy for blindness (MCO-010) was accepted in September 2026; phase 1/2 results for another treatment (GS030) were published in the New England Journal of Medicine on 8 October 2026.
Why does this prize matter?
The brain consists of approximately 86 billion nerve cells and trillions of connections between them. For many years, scientists tried to understand the brain by stimulating it with electrodes, administering drugs or examining damaged regions. The common problem with these methods was their inability to distinguish intertwined cell types: an electrode stimulates all surrounding cells together, while a drug affects the entire brain for hours.
Optogenetics solved both problems together. By using gene transfer to place a light-sensitive protein only in a selected cell type, it became possible to switch those cells on and off with light within milliseconds, at the brain's own speed. In the words of Nobel Assembly Chair Per Svenningsson, optogenetics provided "the opportunity to map the brain in ways we once could only imagine." Assembly member Abdel El Manira emphasized that the method's impact goes far beyond understanding the healthy brain, with implications for conditions such as blindness, depression, addiction and dementia.
The method was selected as "Method of the Year" by Nature Methods in 2010. Perhaps the prize's most important message is this: basic research driven by curiosity about an alga's behavior in moving toward light, in which "no one was interested" in its early years, as Hegemann put it, provided the key to understanding medicine's most complex organ.
What is optogenetics?
Optogenetics is the placement of light-sensitive proteins into specific cells using genetic methods and the control of those cells with light. In the best-known example, the channelrhodopsin gene obtained from green algae is transferred to nerve cells; when blue light is applied, the channel opens and the cell is stimulated. Other light-sensitive proteins silence cells. Selected cells can thus be switched on and off within milliseconds.
Figure 1 · From an alga to the brain: how does optogenetics work?
A simplified summary of the prize-winning discoveries.
Switching the cell on and off: the light-sensitive proteins used
The power of optogenetics also comes from its ability to silence cells as well as stimulate them. Proteins obtained from different microbes and responding to different colors of light form a set of "on-off switches":
| Protein | Source | Light | What does it do? | Effect |
|---|---|---|---|---|
| Channelrhodopsin-2 (ChR2) | Green alga (Chlamydomonas) | Blue | Opens the channel that allows positively charged ions through | Stimulates the cell |
| Halorhodopsin (NpHR) | Archaea living in saline environments | Yellow | Pumps chloride into the cell | Silences the cell |
| ChrimsonR | Alga-derived, red-shifted channelrhodopsin | Orange-amber | Excitatory channel; works with light that reaches deeper | Stimulates the cell; used in blindness treatment (GS030) |
| Bacteriorhodopsin | Halobacteria (identified in 1971) | Green-yellow | Proton pump | Precursor of optogenetics; the first microbial light-sensitive protein |
Figure 2 · Switching on and off in the same cell
Two different light-sensitive proteins can be placed in the same nerve cell.
How is an optogenetic experiment performed?
Figure 3 · Steps of optogenetics in an animal experiment
The general method used in live mice since 2007.
How does optogenetics differ from other methods?
| Method | Cell selectivity | Time precision | Use in humans |
|---|---|---|---|
| Electrode stimulation, deep brain stimulation | Low: all surrounding cells are affected | High (millisecond) | Established treatment in diseases such as Parkinson's |
| Drugs | Low-moderate: all cells carrying the target receptor | Low (minute-hour) | Widespread |
| Transcranial magnetic stimulation | Low: regional | Moderate | Approved for depression |
| Optogenetics | High: only the selected cell type | High (millisecond) | Clinical research only in the eye so far |
Who are the prize winners?
| Scientist | Birth | Institution | Prize-winning contribution |
|---|---|---|---|
| Georg Nagel | 24 August 1953, Weingarten (Germany) | University of Würzburg (since 2004); previously the Max Planck Institute of Biophysics in Frankfurt | Experiments showing that algal channelrhodopsins are light-gated ion channels; in 1995, he had shown that a microbial light-sensitive protein could function in animal cells. |
| Peter Hegemann | 11 December 1954, Münster (Germany) | Humboldt University of Berlin | Deciphered the light-sensing system of green algae; advocated the hypothesis that the light sensor and ion channel are the same protein and developed channelrhodopsins. |
| Karl Deisseroth | 18 November 1971, Boston (USA) | Stanford University; Howard Hughes Medical Institute | Turned optogenetics into a research method by applying channelrhodopsin to mammalian nerve cells; introduced the term in 2006. He is also a psychiatrist who sees patients. |
How did they receive the news?
Nobel Assembly Secretary Thomas Perlmann reported that the three scientists were delighted to share the prize and referred to one another as "my friends." Deisseroth also emphasized that the chosen trio fully represents the path from algal research to brain circuits.
How did the discovery happen?
Who was left out of the prize?
Nobel rules limit a prize to a maximum of three people. Thus, Ernst Bamberg, a co-author of the 2002-2005 publications; Ed Boyden, first author of the 2005 study; Gero Miesenböck, who developed one of the first ways to control nerve cells with light; and Dieter Oesterhelt, a pioneer of microbial light-sensitive proteins, were not on the list this time. Many of these names had previously shared major awards in the same field:
| Award | Year | Recipients |
|---|---|---|
| The Brain Prize | 2013 | Bamberg, Boyden, Deisseroth, Hegemann, Miesenböck, Nagel |
| Breakthrough Prize | 2016 | Boyden, Deisseroth |
| Kyoto Prize | 2018 | Deisseroth |
| Shaw Prize | 2020 | Miesenböck, Hegemann, Nagel |
| Lasker Basic Medical Research Award | 2021 | Oesterhelt, Hegemann, Deisseroth |
| Nobel Prize in Physiology or Medicine | 2026 | Deisseroth, Hegemann, Nagel |
This table reminds us that major scientific discoveries often result from the joint work of many teams. As Hegemann himself noted, he never performed a neuroscience experiment; a fundamental curiosity about algal biology opened the path.
What is optogenetics used for in medicine?
Figure 4 · Optogenetics from laboratory to clinic
The path from basic research to the first authorization application.
Restoring vision: the most advanced application
In inherited diseases such as retinitis pigmentosa, in the retina the light-sensing cells are lost, but other nerve cells in the retina may remain intact for a long time. In optogenetic treatment, a light-sensitive channel gene is transferred into these cells, enabling them to detect light directly. The most important advantage of this approach is that it does not require knowing the gene causing the disease; the same treatment can be used for blindness due to hundreds of different genetic defects.
| Treatment | Developer | Light-sensitive protein and method | Status (October 2026) |
|---|---|---|---|
| MCO-010 (MOGENRY, sonpiretigene isteparvovec) | Nanoscope Therapeutics | Multi-characteristic opsin sensitive to ambient light; a single injection into the eye, no goggles required | FDA authorization application accepted in September 2026; decision expected in the first half of 2027. Priority review in Japan |
| GS030 | GenSight Biologics | ChrimsonR; injection into the eye and special goggles that intensify light | Phase 1/2 (PIONEER) results published in NEJM on 8 October 2026; not approved |
| RST-001 | RetroSense, later Allergan/AbbVie | Channelrhodopsin-2 | First patient treated in 2016; current status not publicly available |
First results in optogenetic gene therapies
Colored bars indicate treatment groups; the gray bar indicates the sham procedure. Mean improvement in visual acuity in the MCO-010 RESTORE study (logMAR; 0,3 corresponds to approximately 3 lines).
RESTORE is a randomized study of 27 patients. Of the treated patients, 40% gained more than 3 lines of vision at week 52 and 56% at week 76. In the GS030 (PIONEER) study, light sensitivity improved significantly in 6 of 10 patients, and 4 of the 8 patients evaluable for object tasks improved. The two studies use different treatments and measures; they cannot be compared directly.
In the PIONEER study, light sensitivity improved significantly in 6 of 10 patients; 4 of the 8 patients evaluable for object tasks performed with special goggles improved. Brain wave measurements suggested that the signal reached the visual cortex. A serious ocular side effect in one patient resolved quickly. The researchers emphasized that the results were "exploratory." No serious side effects were reported in the MCO-010 RESTORE study.
Hearing: a light-driven cochlear implant
Tobias Moser's team in Göttingen is developing a cochlear implant that stimulates auditory nerves in the inner ear with light rather than electricity. Because light can be focused on a much narrower area than electricity, it is expected to provide clearer sound discrimination. The team had aimed to begin the first human study in 2026; a review dated March 2026 reports that the technology is "approaching" this stage but that it has not yet begun.
Brain and mental health research
Optogenetics is used today in laboratories around the world to decipher the brain circuits underlying behaviors such as memory, fear, thirst, sleep, pain and addiction . In animal models of Parkinson's disease, depression, anxiety and addiction, this method can test which cell group is responsible for symptoms. This knowledge contributes to making existing treatments such as deep brain stimulation more targeted and finding new drug targets. Deisseroth's perspective on the field as a psychiatrist is also important here: understanding the biology of mental illnesses remains one of the largest gaps in medicine even today. We discussed the importance of depression in cancer patients in this article .
Contribution to cancer research: cancer neuroscience
Optogenetics is not used directly in cancer treatment; however, it helped give rise to an entirely new research field. In 2015, Michelle Monje's team at Stanford optogenetically stimulated nerve cells in the brain cortex of mice carrying human glioma cells and showed that this activity accelerated tumor growth. A protein secreted by nerve cells, called neuroligin-3, was responsible for this effect. That Monje is the wife of prize winner Karl Deisseroth is an interesting detail of this scientific bridge.
The finding initiated research into treatments targeting communication between nerve cells and tumor cells. Based on this finding, a drug called INCB7839, which inhibits neuroligin-3 release, began to be tested in a phase 1 study (PBTC-056) in children with recurrent high-grade glioma. Safety is being monitored closely because clotting events were reported in previous studies of the same drug in adults. We discussed current treatments for brain tumors in our article on new treatments in high-grade glioma and glioblastoma, and molecular diagnosis in our article on molecular diagnosis in glioblastoma . Brain tumor symptoms and treatment are also covered in our general guide, which you can consult.
- No approved treatment yet: Optogenetics is primarily a research tool today. The first authorization decision is expected in 2027.
- Gene transfer and light are required: Use in humans requires safe gene transfer and delivery of light to the tissue; the first applications therefore focus on the eye, which light can reach easily.
- Treatment in the brain is far off: Knowledge from optogenetics is valuable in mental and neurological illnesses, but optogenetic treatment in the human brain has not yet reached the clinical research stage.
- Beware of "treatment with light" promises: Light therapy devices on the market have no connection with optogenetics; optogenetics is a method requiring genetic modification.
Comparison with the 2025 prize and the connection to Turkey
The 2025 Nobel Prize in Medicine was awarded to Mary Brunkow, Fred Ramsdell and Shimon Sakaguchi, who discovered regulatory T cells and the FOXP3 gene, which prevent the immune system from attacking our own tissues. That discovery contributes directly to treatments for cancer and autoimmune diseases; we described the details in our 2025 Nobel article . The 2026 prize shows how basic science can extend from an alga's behavior of moving toward light to understanding medicine's most complex organ. You can find another example of how fundamental biology changes medicine in our article on the 2017 Nobel Prize in Medicine awarded for circadian rhythm discoveries.
- The Nobel Prize and Turkey: Turkey's only Nobel Prize in science belongs to Prof. Dr. Aziz Sancar, who received the 2015 Nobel Prize in Chemistry for DNA repair mechanisms. We described the contribution of Sancar's discoveries to cancer treatment in this article .
- A shared lesson: Both discoveries arose from research seeking to understand the fundamental biology of microbes, seemingly far from application at first glance. Sancar's studies of DNA repair and circadian rhythm that began in bacteria, like Hegemann's research that began with algae, required many years of patience and support.
- For patients: Patients with retinitis pigmentosa can follow authorization processes for optogenetic gene therapies and clinical trials ; these treatments are not yet available in Turkey.
Frequently asked questions
- Who won the 2026 Nobel Prize in Medicine?
- The prize was awarded to Karl Deisseroth from the USA and German scientists Peter Hegemann and Georg Nagel for their discoveries concerning light-gated ion channels and optogenetics. Announced on 5 October 2026, the prize of 12 million Swedish kronor was divided equally among them.
- What does optogenetics mean?
- It is the placement of light-sensitive proteins into specific cells using genetic methods and switching these cells on and off with light. It is used most commonly in brain research to understand which nerve cell is responsible for which behavior.
- Is optogenetics a treatment method?
- Not yet. As of October 2026, there is no approved optogenetic treatment. The most advanced application is in patients with vision loss due to retinitis pigmentosa; the first gene therapy's authorization application is under review in the USA, and a decision is expected in 2027.
- Is optogenetics related to cancer?
- It is not a direct cancer treatment. However, by showing that nerve cell activity can accelerate the growth of brain tumors, it contributed to the development of cancer neuroscience and led to investigation of a new drug in children with glioma.
Glossary
- Channelrhodopsin
- A protein channel found in green algae that opens with light and allows ions through.
- Halorhodopsin
- A microbial protein that works with yellow light, pumps chloride into the cell and silences the nerve cell.
- Ion channel
- A protein in the cell membrane that allows charged particles to pass; it plays a fundamental role in stimulating nerve cells.
- Opsin
- A family of light-sensing proteins; the visual pigments in the eye also belong to this family.
- Viral vector
- A virus used to carry a gene into a cell, with its ability to cause disease removed.
- Retinitis pigmentosa
- An inherited vision loss disease in which light-sensing cells in the retina are progressively lost.
- Cancer neuroscience
- A new research field examining interactions between the nervous system and cancer cells.
DROZDOGAN Academy Commentary
Research driven by curiosity about an alga moving toward light gave rise to one of the most powerful tools for understanding the brain.
⚡ Why it matters
Optogenetics moved brain research from observing associations to testing cause and effect; it became a fundamental tool for understanding the biology of mental and neurological illnesses.
✅ Strengths
Cell type-specific, reversible control with millisecond precision. First human results in blindness, phase 1/2 data published in a peer-reviewed journal and the first authorization application under FDA review.
⚠️ Limitations
Use in humans requires gene transfer and light delivery. Gains in vision remain partial; therapeutic use in the brain is far off.
🩺 Meaning for patients
Optogenetics is a research tool today; caution is needed with commercial applications promising "treatment with light." For patients with retinitis pigmentosa, authorization processes and clinical trials are worth following.
❓ Open questions
When and how will knowledge from optogenetics translate into treatment for depression, addiction and Parkinson's through drugs or targeted brain stimulation? Will the first optogenetic gene therapy be approved, and how lasting will its gains be?
Conclusion: A long-awaited and highly deserved prize demonstrating the power of basic science. Optogenetics is a tool for understanding the brain today; tomorrow, it has the potential to become a treatment tool, starting with vision loss.
- This article was prepared in October 2026. Prize information and quotations are based on the Nobel Assembly announcement, statements from the prize winners' universities and the international press; German quotations were translated into Turkish.
- Scientific details were taken from original articles and sources from the awarding organizations. Clinical data were compiled from sources reporting company statements and peer-reviewed publications.
- The studies in the chart use different treatments and different measures; they cannot be compared directly with one another.
- The diagrams were derived from verified statements in the text; they contain no new data. The Academy commentary are our own.
Sources
- The Nobel Prize. The Nobel Prize in Physiology or Medicine 2026. nobelprize.org
- STAT. Nobel Prize in medicine awarded for optogenetics (5 October 2026). statnews.com
- Stanford Report. Karl Deisseroth wins Nobel Prize in Physiology or Medicine. stanford.edu
- Stanford Medicine. Deisseroth Nobel Prize. stanford.edu
- The Stanford Daily. Karl Deisseroth 2026 Nobel Prize (6 October 2026). stanforddaily.com
- Ophthalmology Times. 2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery. ophthalmologytimes.com
- Times of Oman. German and US scientists win Nobel Prize in medicine. timesofoman.com
- Tagesspiegel. Nobel Prize in Medicine goes to researchers from Germany and the USA. tagesspiegel.de
- Tagesspiegel. Nobel laureate Hegemann: Research takes courage. tagesspiegel.de
- Nürnberger Nachrichten. Georg Nagel's reaction to the prize news. nn.de
Was this article helpful?
Your feedback helps us improve our content.
